Business Wire

ExaGrid Named a Finalist in SDC Awards 2019

30.10.2019 14:00:00 EET | Business Wire | Press release

Share

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been named a finalist in the Storage, Digitalisation + Cloud (SDC) Awards 2019. The SDC Awards – the new name for Angel Business Communications' IT awards – is firmly focused on recognizing and rewarding success in the products and services that are the foundation for digital transformation. ExaGrid’s EX Series backup storage appliances with data deduplication is nominated for “Backup Storage Innovation of the Year.” Voting to determine the winner in each category is underway now and closes on 15th November 2019 at 17:30 BST. The results will be revealed at an evening gala in London on 27th November 2019.

ExaGrid has gained the nomination due the EX Series’ uniquely scalable architecture and its specialized deduplication process. ExaGrid is best known for its industry-leading approach to backup storage with unique Landing Zone technology, Adaptive Deduplication approach, and cost-effective scale-out architecture. Managing data growth can cause strain on backup storage and ExaGrid set out to develop the best backup target possible. Through its intelligent hyperconverged storage for backup with data deduplication, ExaGrid helps IT organizations solve three of the most pressing issues they face today: how to protect and manage growing data, how to recover data as quickly as possible, and how to do so at a lower cost.

In data backup, organizations retain weekly, monthly and yearly backups in order to account for regulatory audits, legal discovery and other business reasons. It is not uncommon for organizations to retain 20 to 50 copies of their backup data at different historic points in time. As a result, the total backup storage can be 20 to 50 times greater than the initial primary storage copy. The cost of storage for backup becomes prohibitive and difficult to manage. The value that ExaGrid provides stems from its adaptive approach to deduplication, which offers a 20:1 data deduplication ratio. The ExaGrid system can easily scale to accommodate data growth. ExaGrid’s computing software makes the system highly scalable. Appliances of any size or age can be mixed and matched in a single system with capacities of up to a 2PB full backup plus retention and an ingest rate of up to 432TB per hour, which is the highest in the industry. Once virtualized, they appear as a single system to the backup server, and load balancing of all data across servers is automatic reducing IT staff maintenance and time.

The traditional inline approach to backup storage only stores deduplicated data. Therefore, both backups and restores are slow as data is deduplicated and rehydrated. As data grows, no additional compute resources are added – so the backup window grows until backups must be abandoned as they are cutting into production hours. Only an expensive, disruptive, forklift upgrade can resolve the longer backup windows. Instead, ExaGrid writes data straight to a disk Landing Zone for the fastest backups, while deduplication happens in parallel. The most recent backup is kept in undeduplicated form in its Landing Zone for the fastest restores and instant VM recovery, since no rehydration is necessary. Long-term retention data is stored deduplicated in the repository, which is a separate section of the appliance.

“ExaGrid’s nomination demonstrates the importance of innovation in the backup storage space and the need for a continued focus on data storage efficiency and cost savings,” said Bill Andrews, CEO and President of ExaGrid. “ExaGrid’s unique scale-out storage architecture provides all compute, network and storage resources for a fixed-length backup window as data grows. This provides essential time savings for strained IT staff. Our approach also eliminates expensive forklift upgrades and planned product obsolescence, which reduces the total cost of ownership for organizations looking to save storage space in their backup environment.”

ExaGrid supports all backup typologies including private cloud, offsite data center, third-party data center, third-party cloud, public cloud, and can operate in a pure hybrid environment.

Lastly, ExaGrid supports a wide variety of backup applications, utilities, and database dumps, such as Veeam, Commvault, Veritas NetBackup, IBM Spectrum Protect, HYCU, Zerto, Acronis and many others. ExaGrid allows multiple approaches within the same environment. An organization can use one backup application for its physical servers, a different backup application or utility for its virtual environment, and also perform direct Microsoft SQL or Oracle RMAN database dumps – all to the same ExaGrid system. This approach allows customers to use the backup application and utilities of their choosing, use best-of-breed backup applications and utilities, and choose the right backup application and utility for each specific use case. If the customer chooses to change their backup application in the future, the ExaGrid system will still work, protecting the initial investment.

About ExaGrid
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique Landing Zone, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872 x0248

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye